Clinical Study to Evaluate the Efficacy of an Anti-Fungal Supplement

Not Applicable

Completed

• Conditions: Candida Albicans Infection; Candida Infection; Candida Systemic
• Interventions: Other: Placebo; Dietary Supplement: CanXida Remove (Formula RMV)

• Registration Number: NCT06146504
• Lead Sponsor: CanXida

Brief Summary

This is a virtual, double-blind, two-arm, randomized, placebo-controlled clinical trial that will last 12 weeks. Participants will take the CanXida Remove Candida Cleansing Formula RMV or a placebo product daily and complete questionnaires at Baseline, Week 6, and Week 12. Candida microbiome testing will be conducted via stool sample at Baseline and Week 12.

The participants will all be blinded to the name of the test brand.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2023-11-19
• Study First Submitted QC: 2023-11-19
• Study First Posted: 2023-11-24
• Study Start: 2023-11-30
• Primary Completion: 2024-06-28
• Study Completion: 2024-06-28
• Status Verified: 2024-08
• Last Update Submitted: 2024-08-20
• Last Update Posted: 2024-08-22

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 60

Inclusion Criteria

1. Aged between 18-50.

2. Female.

3. Self-reported recurrent vaginal issues, including:

   • Itching and irritation in and around the vaginal area.
   • Burning sensation during urination or sexual intercourse.
   • Abnormal discharge (e.g. thicker, white, and curd-like in appearance, odorless, or with a mild yeasty smell.
   • Redness and swelling of the vulva and surrounding skin
   • Pain or discomfort in the vaginal area or lower abdomen.
   • Urinary tract infections
   • Vaginal thrush

4. May also experience issues with fatigue, lethargy, and gut or digestive issues.

5. Willing to provide two stool samples during the study.

6. Willing to adhere to the study protocol.

7. Willing to avoid introducing any products or any new forms of regular medication or supplements that target candida overgrowth, gut health, or vaginal health for the duration of the study.

Exclusion Criteria

1. Anyone with severe chronic conditions including oncological conditions, psychiatric disease, diabetes, or other.
2. Anyone with known severe allergic reactions or is allergic to the test product or placebo ingredients.
3. Currently taking any antibiotics or will be during the trial period.
4. Anymore diagnosed with a sexually transmitted disease within the last three months e.g. Chlamydia, trichomoniasis, gonorrhea, genital herpes
5. Women who are pregnant, breastfeeding, or attempting to become pregnant.
6. Having any planned invasive medical procedures during the study period.
7. Currently participating in any other clinical study.
8. History of substance abuse.
9. Unwilling to follow the study protocol.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	All participants will adhere to the following treatment regime: Day 1-7: 1 tablet per day Day 8-22: 2 tablets per day Day 23- 84: 3 tablets per day The product should always be taken with the first meal of the day.
CanXida Supplement	CanXida Remove (Formula RMV)	All participants will adhere to the following treatment regime: Day 1-7: 1 tablet per day Day 8-22: 2 tablets per day Day 23- 84: 3 tablets per day The product should always be taken with the first meal of the day.

Primary Outcome Measures

Name	Time	Method
Changes in growth of candida in the gut. [Timeframe: Baseline to Week 12]	12 weeks	Measured via gut microbiome analysis. Participants will provide a stool sample for the analysis.

Secondary Outcome Measures

Name	Time	Method
Changes in vaginal health symptoms. [Timeframe: Baseline to Week 12]	12 weeks	Measured via study-specific questionnaires. Questionnaires will use a Likert scale (0-5 scale) to measure changes in vaginal itching, vaginal discharge, vaginal discomfort. On the scale, 0= the least favourable score and 5= the most favourable score.
Changes in self-reported energy levels. [Timeframe: Baseline to Week 12]	12 weeks	Measured via study-specific questionnaires using a 5-point Likert scale. 0= the most favourable and 5= the least favourable response.
Changes in scores on the Gastrointestinal Symptom Rating Scale (GSRS). [Timeframe: Baseline to Week 12]	12 weeks	The GSRS is a disease-specific instrument of 15 items combined into five symptom clusters depicting Reflux, Abdominal pain, Indigestion, Diarrhoea and Constipation. The GSRS has a seven-point graded Likert-type scale where 1 represents absence of troublesome symptoms and 7 represents very troublesome symptoms.
Changes in scores on the Bristol Stool Scale. [Timeframe: Baseline to Week 12]	12 weeks	The Bristol Stool Scale is a scale that classifies stools, ranging from the hardest to the softest. Experts consider types 1 and 2 to be uncharacteristically hard and indicative of constipation, while types 6 and 7 are unusually loose and may indicate diarrhea. Medical professionals generally consider types 3, 4, and 5 to be the most typical.

Trial Locations

Locations (1)

Citruslabs; 🇺🇸 Santa Monica, California, United States